Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Nagourney

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Medicinal Food|December 24, 2002
PC-SPESRobert A Nagourney
Current Treatment Options in Oncology|February 4, 2006
Ex vivo programmed cell death and the prediction of response to chemotherapyRobert A Nagourney
Journal of Medicinal Food|January 20, 2011
Medicinal food meets epigeneticsRobert A Nagourney, Sheldon S Hendler
Journal of Medicinal Food|December 15, 2012
Sheldon S. Hendler, PhD, MD (1936-2012)Joyce Hendler, Ross Hendler, Robert A Nagourney, et al.
Gynecologic Oncology|April 29, 2006
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology GroupCheryl A Brewer, John A Blessing, Robert A Nagourney, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2020
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatinRobert A Nagourney, Steven Evans, Peter H Tran, et al.
Case Reports in Medicine|October 24, 2013
Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular PhonesJohn G West, Nimmi S Kapoor, Shu-Yuan Liao, et al.
Gynecologic Oncology|November 8, 2005
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupCheryl A Brewer, John A Blessing, Robert A Nagourney, et al.
Clinical Breast Cancer|October 28, 2008
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancerRobert A Nagourney, Marshall Flam, John Link, et al.
SAGE Open Medical Case Reports|March 28, 2019
Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapyPedro Luiz Serrano Usón Junior, Jairo Wagner, Marcus Vinicius de Nigro Corpa, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Food|December 24, 2002
PC-SPESRobert A Nagourney
Current Treatment Options in Oncology|February 4, 2006
Ex vivo programmed cell death and the prediction of response to chemotherapyRobert A Nagourney
Journal of Medicinal Food|January 20, 2011
Medicinal food meets epigeneticsRobert A Nagourney, Sheldon S Hendler
Journal of Medicinal Food|December 15, 2012
Sheldon S. Hendler, PhD, MD (1936-2012)Joyce Hendler, Ross Hendler, Robert A Nagourney, et al.
Gynecologic Oncology|April 29, 2006
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology GroupCheryl A Brewer, John A Blessing, Robert A Nagourney, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 2, 2020
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatinRobert A Nagourney, Steven Evans, Peter H Tran, et al.
Case Reports in Medicine|October 24, 2013
Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular PhonesJohn G West, Nimmi S Kapoor, Shu-Yuan Liao, et al.
Gynecologic Oncology|November 8, 2005
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupCheryl A Brewer, John A Blessing, Robert A Nagourney, et al.
Clinical Breast Cancer|October 28, 2008
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancerRobert A Nagourney, Marshall Flam, John Link, et al.
SAGE Open Medical Case Reports|March 28, 2019
Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapyPedro Luiz Serrano Usón Junior, Jairo Wagner, Marcus Vinicius de Nigro Corpa, et al.
Pageof 2